Prostatic acid phosphatase is expressed in human prostate cancer bone metastases and promotes osteoblast differentiation

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 64-70

  Kirschenbaum, Alexander ^a   Liu, Xin Hua ^a   Yao, Shen ^b   Leiter, Amanda ^b   Levine, Alice C ^b  

^a Department of Urology and Medicine ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastases; Osteoblasts; Prostate cancer; Prostatic acid phosphatase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TARTARIC ACID;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOBLAST; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 81255210489     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06198.x     Document Type: Article

References (32)

1. Mundy, G.R. 2002. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2: 584-593.
2. Zhang J., J. Dai, Y. Qi, et al 2001. Osteoprotogerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107: 1235-1244.
3. Jacobs, S.C. 1983. Spread of prostatic carcinoma to bone. Urology 21: 337-344.
4. Berry, S., T. Waldron, E. Winquist & H. Lukka 2006. The use of bisphosphonates in men with prostate cancer: a systematic review of randomized trials. Can. J. Urol. 13: 3180-3188.
5. Fizazi, K, M. Carducci, M. Smith, et al 2011. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double blind study. Lancet 377: 813-822.
6. Sturge, J., M.P. Caley & J. Waxman 2011. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Rev. Clin. Oncol. 8: 357-368.
7. Liu, X.H., A. Kirschenbaum, S. Yao, G. Liu, et al 2007. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 67: 5747-5753.
8. Gutman, E.B, E.E. Sproul & A.B. Gutman 1936. Significance of increased phosphatase activity at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am. J. Cancer 28: 485-495.
9. Huggins, C. & C.V. Hodges 1941. Studies on prostatic cancer: the effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293-297.
10. Steineck, G., W.K. Kelly, M. Mazumdar, et al 1996. Acid phosphatase: defining a role in androgen-independent prostate cancer. Urology 47: 719-726.
11. Taira, A., G. Merrick, K. Wallner & M. Dattoli 2007. Reviving the acid phosphatase test for prostate cancer. Oncology 21: 1003-1010.
12. Li, H.C., J. Chernoff, L.B. Chen & A. Kirschenbaum 1984. A phosphotyrosyl-protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 138: 45-51.
13. Hassan, M.I., A. Aijaz & F. Ahmad 2010. Structural and functional analysis of human prostatic acid phosphatase. Expert Rev. Anticancer Ther. 107: 1055-1068.
14. Li, S., R. Loberg, J. Liao, et al 2009. A destructive cascade mediated by CLL2 facilitates prostate cancer growth in bone. Cancer Res. 69: 1685-1692.
15. Kirschenbaum, A., D.R. Liotta, S. Yao, et al 2000. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J. Clin. Endocrinol. Metab. 85: 3436-3441.
16. Rohde, M. & H. Mayer 2007. Exocytotoic process as a novel model for mineralizaton by osteoblastsin vitroandin vivodetermined by electron microscopic analysis. Calcif. Tissue Int. 80: 323-336.
17. Fowler, J.E., Jr., N.T. Brawell, P. Pandey, et al 1995. Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center. J. Urol. 153: 1020-1031.
18. Zagars, G.K., A.C. von Eschenbach & A.G. Ayala 1993. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 72: 1709-1726.
19. Zagars, G.K., A. Pollack & A.C. von Eschenbach 1997. Prognostic factors for clinically localized prostate carcinoma: anlaysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79: 1370-1380.
20. Han, M., S. Piantadosi, M.L. Zahurak, et al 2001. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57: 707-711.
21. Fang, L.C., M. Dattoli, K. Wallner, et al 2007. Prostatic acid phosphatase predicts cancer-specific survival after palladium-103 brachytherapy for prostate cancer. Brachytherapy 6: 79-80.
22. Merrick, G.S., W.M. Butler, K. Wallner, et al 2005. Enzymatic prostatic acid phosphatase in the clnical staging of patients diagnosed with prostate cancer. W. V. Med. J. 101: 116-119.
23. Ozu, C., J. Nakashima, Y. Horiguchi, et al 2008. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int. J. Urol. 15: 419-422.
24. Kantoff, P.W. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363: 411-422.
25. Longo, D.L. 2010. Editorial: new therapies for castration-resistant prostate cancer. New Engl. J. Med. 363: 479-482.
26. Vihko, P. 1978. Characterization of the principal human prostatic acid phosphatase isoenzyme, purified by affinity chromatography and isoelectric focusing. Part II. Clin. Chem. 24: 1783-1787.
27. Zimmerman, L.B., J.M. DeJesus-Escobar & R.M. Harland 1996. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86: 599-606.
28. Ye, L., M.D. Mason & W.G. Jiang 2011. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci. 16: 865-897.
29. Ye, L., J.M. Lewis-Russell, H. Kynaston & W.G. Jiang 2007. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J. Urol. 8(Pt 1): 1086-1091.
30. Kirsch, T., J. Nickel & W. Sebald 2000. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 19: 3314-3324.
31. Horvath, L.G., S.M. Henshall, J.G. Kench, et al 2004. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59: 234-242.
32. Carducci, M.A., et al 2007. A phase 3 randomized trial of the efficancy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966.